Friday, March 28, 2025 | 07:13 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

WHO stands by action of issuing alert against Maiden Pharma cough syrup

Asserts that testing done in labs in Ghana and Switzerland confirmed excess levels of contaminated syrups that are "dangerous and should not be in any medicine, ever"

cough syrup, medicine, cold
Premium

File photo of cough syrup | Photo: Shutterstock

Sohini Das
As the issue of contaminated cough syrups linked by the WHO to children deaths in Gambia escalates with the Indian regulator clearing the cough syrup samples after testing, the global agency says it stands by the action it took--that of issuing an alert.

Responding to queries sent by Business Standard, WHO spokesperson said: "When many children die of mysterious sickness, it’s a tragedy (and) that means WHO had to act quickly." Justifying its quick action, the WHO further added that "WHO-contracted laboratories in Ghana and Switzerland tested the suspected cough syrups products from The Gambia and confirmed excess levels of ethyleneglycol

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in